Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's Aducanumab And Three Other Drugs Get First EU PRIME Designations

Executive Summary

The European Medicines Agency has announced the names of the first four drugs to be accepted onto its new priority medicines scheme, including Biogen Inc.'s aducanumab for Alzheimer's disease. But the agency also turned down 14 other applications for PRIME eligibility.

You may also be interested in...



Gilead Confronts New Attacks On Pricing, Patents

Gilead Science Inc. was slammed with a pair of attacks against the way it markets its hepatitis C virus (HCV) drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) and its HIV/AIDS medicines containing tenofovir – with one punch coming from a new foe, the Massachusetts Attorney General Maura Healey, and the other from one of its longtime antagonists, the AIDS Healthcare Foundation (AHF).

Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging

Biogen Inc. has earmarked $100m for business development in 2016, an investment the company hopes to take advantage of if the financial markets continue to be challenging for young biotechs, driving down valuations for assets.

UK Confirms It Will Accept EU Marketing Authorizations For Two Years

New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel